Remove tag ukraine
article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S.

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products.

Pharma 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”. Click here to watch this webinar and access the presentation. Free Report What is the Global Healthcare and Pharma Market Q2 Outlook?

Marketing 102
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a 5.1%

Medical 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a 5.1%

Medical 98